http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022150530-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bcf383f7f43b14e27a6e0c4b775626c6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-88 |
| filingDate | 2022-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fdc9764db05cbd7430a03a022e28303 |
| publicationDate | 2022-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022150530-A1 |
| titleOfInvention | Protected alkyl tryptamines and their therapeutic uses |
| abstract | The disclosure relates to protected alkyl tryptamine compounds of formula (I). The disclosure relates to compositions comprising, consisting essentially of, or consisting of a compound of formula (I) and an excipient. The disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) where the excipient is a pharmaceutically acceptable carrier. The disclosure further relates to therapeutic uses of compounds of formula (I). |
| priorityDate | 2021-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 672.